DISCOVER OUR PIPELINE IN HUMAN MEDICINE

Neuroscience, Oncology, Cardiovascular, Dermatology, Rare Diseases Small Molecule is the key
2017

MIC4578 (Chronic Pain)

NeuroscienceSmall Molecule
  • Screening
  • Hit to Lead
  • Lead optimization
  • Preclinical
  • IND
  • Clinical I,II,III
2018

MIC6479 (Pancreatic Cancer)

OncologySmall Molecule
  • Screening
  • Hit to Lead
  • Lead optimization
  • Preclinical
  • IND
  • Clinical I,II,III
2017

MIC8411 (Melasma)

DermatologySmall Molecule
  • Screening
  • Hit to Lead
  • Lead optimization
  • Preclinical
  • IND
  • Clinical I,II,III
2017

MIC9211 (Alcoholism: alcohol use disorder)

NeuroscienceSmall Molecule
  • Screening
  • Hit to Lead
  • Lead optimization
  • Preclinical
  • IND
  • Clinical I,II,III
2017

MIC2211 (Hyperekplexia rare disease)

NeuroscienceRare DiseasesSmall Molecule
  • Screening
  • Hit to Lead
  • Lead optimization
  • Preclinical
  • IND
  • Clinical I,II,III
2017

MIC2231 (Stiff person syndrome rare disease)

NeuroscienceRare DiseasesSmall Molecule
  • Screening
  • Hit to Lead
  • Lead optimization
  • Preclinical
  • IND
  • Clinical I,II,III
2017

MIC2634 (Iminoglycinuria rare disease)

NeuroscienceRare DiseasesSmall Molecule
  • Screening
  • Hit to Lead
  • Lead optimization
  • Preclinical
  • IND
  • Clinical I,II,III
2017

MIC6701 (Colorectal cancer)

OncologySmall Molecule
  • Screening
  • Hit to Lead
  • Lead optimization
  • Preclinical
  • IND
  • Clinical I,II,III
2017

MIC2091 (Cardiomyopathy)

CardiovascularSmall Molecule
  • Screening
  • Hit to Lead
  • Lead optimization
  • Preclinical
  • IND
  • Clinical I,II,III
2017

MIC8471 (Acne)

DermatologySmall Molecule
  • Screening
  • Hit to Lead
  • Lead optimization
  • Preclinical
  • IND
  • Clinical I,II,III
2018

NEW SMALL MOLECULE FOR DISEASE HERE

Small Molecule
  • Screening
  • Hit to Lead
  • Lead optimization
  • Preclinical
  • IND
  • Clinical I,II,III

DISCOVER OUR PIPELINE IN VETERINARY MEDICINE - companion animals

2017

MIC2041 (Cardiomyopathy HCM)

Small Molecule
  • Discovery, Lead Opportunity (Medicinal Chemistry)
  • Target / Mode of Action
  • In vitro Efficacy
  • Rodent Testing (Efficacy, ADME, Toxicology)
  • POC in Target species
  • Clinical Testing
2017

MIC2011 (Cardiomyopathy DCM)

Small Molecule
  • Discovery, Lead Opportunity (Medicinal Chemistry)
  • Target / Mode of Action
  • In vitro Efficacy
  • Rodent Testing (Efficacy, ADME, Toxicology)
  • POC in Target species
  • Clinical Testing
2017

MIC4578 (Chronic Pain)

Small Molecule
  • Discovery, Lead Opportunity (Medicinal Chemistry)
  • Target / Mode of Action
  • In vitro Efficacy
  • Rodent Testing (Efficacy, ADME, Toxicology)
  • POC in Target species
  • Clinical Testing
2018

MIC1153 (Pancreatic Cancer)

Small Molecule
  • Discovery, Lead Opportunity (Medicinal Chemistry)
  • Target / Mode of Action
  • In vitro Efficacy
  • Rodent Testing (Efficacy, ADME, Toxicology)
  • POC in Target species
  • Clinical Testing
2017

MIC6701 (Colorectal cancer)

Small Molecule
  • Discovery, Lead Opportunity (Medicinal Chemistry)
  • Target / Mode of Action
  • In vitro Efficacy
  • Rodent Testing (Efficacy, ADME, Toxicology)
  • POC in Target species
  • Clinical Testing
2018

NEW SMALL MOLECULE FOR VETERINARY DISEASE HERE

Small Molecule
  • Discovery, Lead Opportunity (Medicinal Chemistry)
  • Target / Mode of Action
  • In vitro Efficacy
  • Rodent Testing (Efficacy, ADME, Toxicology)
  • POC in Target species
  • Clinical Testing

We sell the most smallest & most expensive products in the world!

Please email us: partner@micar21.com

21
Partners


32802
Working
hours

122270
Scanning
compounds

27
Promising
drug
candidates

Development Stages

Level 1. Target identification: Therapeutic target identified

Level 2. Target validation: Therapeutic target undergoes validation in appropriate models

Level 3. Therapeutic identification: Small molecule or biologic with potential for therapeutic effect is identified

Level 4. Therapeutic design: Lead molecule is identified

Level 5. Therapeutic optimization: Lead compound is optimized. Clinical development plan is prepared

Level 6. Preclinical I: Pharmacologic/animal model studies demonstrating proof-of-principle are performed
Preclinical drug development stages. Following identification of a drug target and candidate compounds, several early activities, such as pharmacology, in vivo efficacy, and experimental toxicology, can contribute to the selection of a lead candidate for preclinical development. These preclinical activities provide the basis for an Investigational New Drug (IND) application to the FDA for permission to initiate clinical testing in humans. ADME, absorption, distribution, metabolism, and excretion; API, active pharmaceutical ingredient; PK, pharmacokinetics; Prep, preparation; Tox, toxicity.
Preclinical flow diagram. The parallel and inter-related activities contributing to preclinical development are summarized with color coding to denote related components: manufacturing (red), analytical (grey), documentation (orange), safety (blue), clinical (green). API, active pharmaceutical ingredient; CMC, chemistry, manufacturing, and controls; FDA, US Food and Drug Administration; GLP, good laboratory practice; GMP, good manufacturing practice; ICF, informed consent form; IND, Investigational New Drug; PK, pharmacokinetics.

Level 7. Preclinical II: Dose-finding/characterization studies are performed

Level 8. Preclinical III: Toxicology/safety studies are completed
Cash flow 'Valley of Death' diagram. The cash flow 'Valley of Death' as a function of development stage (time) with typical funding sources at various stages (adapted from). RAID, Rapid Access to Interventional Development; SBIR, Small Business Innovative Research; RAPID, Rapid Access to Preventive Intervention Development; STTR, Small Business Technology Transfer.

Level 9. Clinical Phase I: Human testing on a small-scale basis

Level 10. Clinical Phase II: Controlled clinical testing has been conducted in a relatively small number of patients

Level 11. Clinical Phase III: Clinical testing in large patient populations

Level 12. Patient use: Clinical trials completed and technology approved and available for use – post-marketing surveillance (if required) ongoing

Basic Research

Level 1. Target identification

Therapeutic target identified

Level 2. Target validation

Therapeutic target undergoes validation in appropriate models Identification

Level 3. Therapeutic identification

Drug: Small molecule or biologic with potential for therapeutic effect is identified

In vitro/In vivo

Level 4. Therapeutic design

Lead molecule is identified

Level 5. Therapeutic optimization

Lead compound is optimized. Clinical development plan is prepared.

Preclinical POC

Level 6. Preclinical I

Pharmacologic/animal model studies demonstrating proof-of-principle are performed

Preclinical Regulatory

Level 7. Preclinical II

Dose-finding/characterization studies are performed

Level 8. Preclinical III

Drug: Toxicology/safety studies are completed

Clinical

Level 9. Clinical Phase I

Human testing on a small-scale basis

Level 10. Clinical Phase II

Controlled clinical testing has been conducted in a relatively small number of patients

Level 11. Clinical Phase III

Clinical testing in large patient populations

Patient use

Level 12. Patient use

Clinical trials completed and technology approved and available for use – post-marketing surveillance (if required) ongoing